Showing 901 - 920 results of 933 for search '"virology"', query time: 0.06s Refine Results
  1. 901

    Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study by Hanan M. Fayed, Ali A. Ghweil, Mona M. AbdelMeguid

    Published 2019-01-01
    “…Therapy results in achievement of sustained virological response in 92% of cases, liver function improvement, and normalization of the inflammatory monocytes subsets. …”
    Get full text
    Article
  2. 902

    Influenza forecasting in human populations: a scoping review. by Jean-Paul Chretien, Dylan George, Jeffrey Shaman, Rohit A Chitale, F Ellis McKenzie

    Published 2014-01-01
    “…Five studies used data assimilation methods to update forecasts with new surveillance data. Models used virological (N = 14), syndromic (N = 13), meteorological (N = 6), internet search query (N = 4), and/or other surveillance data as inputs. …”
    Get full text
    Article
  3. 903

    BIOTECHNOLOGICAL SYSTEM FOR THE SEARCH OF SUBSTANCES WITH POTENTIAL ACTIVITY AGAINST CORONAVIRUS by M.P. Smetiukh, O.P. Trokhimenko, S.O. Soloviov, I.V. Dziublyk, O.A. Kamatskyi, I.V. Savchuk, N.A. Bobyr

    Published 2024-12-01
    “…The obtained system "ВНК-21 cell culture + IBV H-120," cultivated at 37 °C in a 5% CO2 atmosphere, can be recommended for use in further biotechnological and virological studies, particularly for evaluating the antiviral activity of potential drugs against coronaviruses.…”
    Get full text
    Article
  4. 904
  5. 905

    Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic r... by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

    Published 2025-02-01
    “…However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. The sustained virologic response (SVR) rates were analyzed using the Freeman–Tukey double arcsine transformation in a random-effects model in R4.1.0 software.ResultsWe recruited 3,177 patients with HCV GT3 in 19 studies from 9 countries. …”
    Get full text
    Article
  6. 906

    The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection by N. D. Yuschuk, S. L. Maximov, L. M. Ivanova, Ye. K. Klimova, O. O. Znoyko, A. V. Kravchenko

    Published 2009-02-01
    “…The rate of achievement of sustained virologic response as a result of therapy of CHC at the HIVinfected patients is comparable to that for CHC patients without HIV-infection. …”
    Get full text
    Article
  7. 907

    Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review by William P. Hanage, William Schaffner

    Published 2024-12-01
    “…To this end, multiple regional, national, and global virologic and disease surveillance systems have been established to provide accurate knowledge of viral epidemiology, support appropriate preparedness and response to potential outbreaks, and help inform prevention strategies to reduce disease severity and transmission. …”
    Get full text
    Article
  8. 908

    Protective potential of structural proteins of the SARS-CoV-2 virus in protecting against COVID-19 by Inna V. Dolzhikova, Daria M. Grousova, Ilya D. Zorkov, Anna A. Ilyukhina, Anna V. Kovyrshina, Olga V. Zubkova, Olga D. Popova, Tatiana A. Ozharovskaya, Denis I. Zrelkin, Daria M. Savina, Ekaterina G. Samokhvalova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Denis Yu. Logunov, Alexander L. Gintsburg

    Published 2024-12-01
    “…Recombinant adenoviral vectors rAd5-S, rAd5-N, rAd5-M were used for immunization of animals. Various genetic, virological and immunological methods, as well as methods of working with animals, were used in the study. …”
    Get full text
    Article
  9. 909

    Predictors of response to daclatasvir in addition to sofosbuvir in hepatitis C virus-infected patients with stage 4 and 5 chronic kidney disease and patients on maintenance hemodia... by Rasha Gawish, Eman Elgohary, Mona Tahoun, Mona Elkaraly, Heba Mohsin, Ahmed Kamal

    Published 2025-01-01
    “…Results Only 29 patients achieved sustained virologic response (SVR) (52.7%). Non-responders had statistically significantly lower hemoglobin, platelets, and albumin, while they had higher INR, liver enzymes, bilirubin, and APRI scores. …”
    Get full text
    Article
  10. 910

    Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China by Chengguang Hu, Guosheng Yuan, Junwei Liu, Huaping Huang, Yanyu Ren, Yinping Li, Xuefu Chen, Wei Li, Tao Wu, Hong Deng, Yanzhong Peng, Yong-Yuan Zhang, Yuanping Zhou

    Published 2018-01-01
    “…The primary observation point was the percentage of patients with a sustained virologic response (SVR) at posttreatment week 12 (SVR12), and all adverse events were monitored during treatment and follow-up period. …”
    Get full text
    Article
  11. 911

    Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review by William R. Short, Parul Patel, Gustavo Verdier, Ana Puga, Vani Vannappagari, Annemiek de Ruiter, Bryn Jones

    Published 2024-12-01
    “…Two studies evaluated DTG/3TC during pregnancy and both reported high virologic suppression rates [HIV-1 ribonucleic acid (RNA) < 50 copies/mL at delivery: 97% (30/31) overall], no events of vertical transmission, and no new safety signals, consistent with the use of DTG-based 3-drug regimens in pregnancy. …”
    Get full text
    Article
  12. 912

    Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene. by Min Zhang, Karim Mouzannar, Zhensheng Zhang, Yuji Teraoka, Jason Piotrowski, Yuji Ishida, Chise Tateno-Mukaidani, Takeshi Saito, Hiromi Abe-Chayama, Kazuaki Chayama, T Jake Liang

    Published 2025-01-01
    “…Individuals infected with these two subtypes appear to have different clinical manifestations and virologic features. Whether such a difference results from the virus or host has not been established. …”
    Get full text
    Article
  13. 913

    ANALYSIS OF GENETIC CHARACTERISTICS OF INFLUENZA VIRUS A/CHICKEN/CHELYABINSK/30/2019 H9N2 ISOLATED IN CHELYABINSK OBLAST by N. G. Zinyakov, Щю S. Osipova, P. B. Akshalova, V. Yu. Sosipatorova, A. V. Andriyasov, D. B. Andreychuk, I. A. Chvala

    Published 2019-12-01
    “…The H9N2 subtype of the isolated virus was identifi ed based on virological analysis. Sequencing of the hemagglutinin gene segment revealed that the amino acid sequence at the cleavage site was RSSR/GLF, which is characteristic of a low virulent avian infl uenza virus. …”
    Get full text
    Article
  14. 914

    Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B by Qianqian Ma, Junzhao Ye, Ling Luo, Yanhong Sun, Wei Wang, Shiting Feng, Bing Liao, Bihui Zhong

    Published 2025-02-01
    “…Their changes in biochemical, virological, and fibrosis parameters and the elevation of AFP or development of HCC during follow-up were analyzed. …”
    Get full text
    Article
  15. 915

    Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study by Mercy T. Mutambanengwe-Jacob, Charles C. Maponga, K. Rivet Amico, Bernard Ngara, Nonhlanhla Yende-Zuma, Tariro D. Chawana, Teacler Nematadzira, Justice F. Gumbo, Tendayi Goverayi, Petronella Matibe, Bernadette V. Malunda, Jim Aizire, Taha E. Taha, Mary G. Fowler, Lynda Stranix-Chibanda

    Published 2022-01-01
    “…We piloted the combined effectiveness of point-of-care viral load monitoring plus motivational enhanced adherence counseling (intervention) compared with routine care (control) in women identified at risk of virologic failure in the PROMOTE study in Zimbabwe. …”
    Get full text
    Article
  16. 916

    Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) by I. Yu. Pirogova, N. B. Kovaleva, E. P. Patlusov, E. S. Radchenko

    Published 2018-08-01
    “…Treatment response was defined by the frequency of sustained virologic response (SVR) achievement. All patients were included in the treatment safety analysis. …”
    Get full text
    Article
  17. 917

    Results of the ORION open comparative randomized trial: evaluation of efficacy of the Russian drugs Altevir and Phosphogliv in combined treatment of chronic hepatitis C by V. T. Ivashkin, M. V. Mayevskaya, P. O. Bogomolov, I. G. Nikitin, A. O. Buyeverov, A. V. Lapshin

    Published 2012-11-01
    “…Statistically significant differences in dynamics of viral load and frequency of achievement of sustained virologic response in patients with identical HCV genotype between groups A and B was revealed. …”
    Get full text
    Article
  18. 918

    HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation by Juliet A. Emamaullee, Mariusz Bral, Glenda Meeberg, Aldo J. Montano-Loza, Vincent G. Bain, Kelly Warren Burak, David Bigam, A. M. James Shapiro, Norman Kneteman

    Published 2019-01-01
    “…In the study period, 128 adult LT were performed. 44 patients were HCV+, and 68.2% (N=30) also had HCC. 38.6% (N=17) of HCV+ patients received DAA pre-LT, and 94.1% (N=16/17) achieved sustained virologic response (SVR) pre-LT. Among untreated HCV+ patients who underwent LT, 81.5% (N=22/27) received DAA post-LT, with 82.6% achieving SVR post-LT (N=18/22). 82.1% (N=23/28) of untreated post-LT patients underwent liver biopsy prior to therapy, and 52.2% had at least F1 METAVIR fibrosis. 87.5% (N=14/16) of active waitlist patients received DAA and achieved SVR. …”
    Get full text
    Article
  19. 919

    Vertical transmission of Severe Acute Respiratory Syndrome Coronavirus 2: A scoping review. by Lemi Belay Tolu, Alex Ezeh, Garumma Tolu Feyissa

    Published 2021-01-01
    “…<h4>Conclusion</h4>Currently there is not enough evidence on vertical virologic transmission of COVID-19 infection during the third trimester of pregnancy. …”
    Get full text
    Article
  20. 920

    Body mass index, proteinuria and total lymphocyte counts in predicting treatment responses among ART naïve individuals with HIV initiated on antiretroviral treatment in Dar es Sala... by Ellen Hertzmark, Patricia Munseri, Lazaro Jassely, Basil Tumaini

    Published 2022-06-01
    “…Objectives To explore the potential use of body mass index (BMI), proteinuria and total lymphocyte count changes in predicting immunological and virological response in individuals with HIV initiated on antiretroviral treatment (ART).Design Prospective cohort study.Setting Three urban HIV care and treatment centres in Dar es Salaam.Participants Individuals with HIV initiating ART.Outcome measures HIV viral load ≥1000 copies/mL (viral non-suppression) at 6 months after ART initiation.Results Of 215 (out of 220 enrolled) participants who returned for evaluation at 6 months, 147 (66.8%) were women. …”
    Get full text
    Article